Compare Manulife Financial Corporation (MFC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Manulife Financial Corporation vs Revvity Inc — how do they compare? Manulife Financial Corporation trades at $43.58 (market cap $69.48B), while Revvity Inc trades at $152.05 (market cap $16.98B). The key difference: Manulife Financial Corporation is far larger — about 4.1× Revvity Inc's market cap, and Manulife Financial Corporation pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Manulife Financial Corporation for 119 Days and Revvity Inc for 12 Days on average.
| MFC | RVTY | |
|---|---|---|
Market Cap | $69.48B | $16.98B |
Volume | 1,347,508 | 1,456,900 |
Sector | Financials | Health |
52-Week High | $44.77 | $157.36 |
52-Week Low | $31.64 | $82.26 |
Typical Hold Time | 119 Days | 12 Days |
Enterprise Value | $64.75B | $19.30B |
Dividend Yield | 3.23% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Manulife Financial (MFC) trades at $41.67, down 2.94% on the day, with a bearish technical signal from moving averages and oscillators. Revenue grew to $53.01B in 2025, with net income of $5.78B and a P/E of 16.22. Recent news includes a new $750M subordinated notes offering and executive appointments, while institutional investors like Bank of America added positions in Q2 2026.
The outlook is mixed: analyst consensus is Buy with a $34.24 target, but technicals suggest near-term pressure. Upside drivers include strong insurance sales and Asia growth, while risks involve premium valuation and macroeconomic sensitivity. Cash flow trends show improved operations, but net cash flow declined in 2025.
RVTY trades at $153.60, up 0.2% today and near its 52-week high of $158.28 (Defense World, 2026-10-01). The stock shows a bullish technical trend with strong moving average signals and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of a CE-IVDR-certified T1D screening kit in Europe (Business Wire, 2026-09-24) and the acquisition of Human Cell Design to expand metabolic disease research tools (Business Wire, 2026-09-09).
The outlook is positive, supported by earnings momentum, strategic acquisitions, and analyst optimism. However, the stock trades at a premium valuation with a P/E of 73.15, and near-term risks include margin pressures in China and rich valuation limiting upside beyond consensus targets. Revenue stability but slight profit margin compression in 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Manulife Financial Corporation
Manulife provides life insurance and wealth management products and services to individuals and group customers in Canada, the United States, and Asia. Manulife is one of Canada's Big Three Life Insurance companies (the other two are Sun Life and Great West Life). As of Dec. 31, 2021, Manulife reported assets under management or administration of about CAD $1.4 trillion.
Read more on MFC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
